The pre-treatment neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and red cell distribution width predict prognosis in patients with laryngeal carcinoma

Abstract

The aim of this study was to identify the potential prognostic roles of the preoperative neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and red cell distribution width (RDW) in patients with laryngeal squamous cell carcinoma (LSCC). 81 patients who underwent surgery for the larynx carcinoma were enrolled in the study. NLR, PLR and RDW were used as outcome measures. Local recurrence was detected in 30 (37.0 %) patients and neck lymph node metastasis was detected 6 (7.4 %) patients during follow-up period. Mortality was seen in 7 (8.6 %) patients. The mean PLR in the T1 and T2 stage tumors were significantly lower than the T4 stage. The mean RDW and PLR were significantly higher in the exitus group than the survivor group. The mean NLR in the patients with local recurrence was significantly higher than the non-recurrent patients. Progression-free survival (PFS) was lower in patients with high NLR. When analyzed by the Cox regression analysis of factors affecting the local recurrence, NLR was found to significantly affect the recurrence. According to ROC analysis for mortality, NLR was not found to be a prognostic factor, although the PLR and RDW were significant prognostic factors. According to Cox regression analysis, a high PLR increases mortality 4.2 times and a high RDW 4.6 times. Although in univariate analysis MCV, RDW and tumor grade were predictors of mortality, RDW and tumor grade independent predictors were found. Further studies involving large patient groups are required.

Platelet count and platelet‐lymphocyte ratio as prognostic markers for head and neck squamous cell carcinoma: Meta‐analysis

“…Therefore, meta-analyses were conducted with a random effect model, using Comprehensive Meta-Analysis version 2 (Biostat, Englewood, NJ). However, only 4 studies 38,42,44,46 were subjected to subgroup analyses for disease sites because the other studies reported the HRs of patients with different affected sites together. Most of the included studies dichotomized patients into 2 groups according to the platelet count or PLR.…”

“…The HRs for DSS were reported in 3 studies and ranged from 0.95 to 1.62; none were statistically significant 37,39,51 ( Figure 2B). Table 2 37,38,[41][42][43][44][45][46]51 shows the characteristics of the included studies for PLR analysis. The pooled HR for DSS was 1.13 (95% CI 0.90-1.43), and the result was not statistically significant.…”

“…The pooled analysis for the 3 studies involved 1956 patients and is shown in Figure 2B. 38,[41][42][43][44][45][46]51 The outcomes analyzed in these studies were OS in 7 studies 37,38,[41][42][43][44]46 and DSS in 3 studies. The result was similar when any individual study was removed from the analysis (Supporting Information Figure S1B).…”

“…Table 2 37,38,[41][42][43][44][45][46]51 shows the characteristics of the included studies for PLR analysis. 38,[42][43][44]46 Cutoff values for dichotomization ranged from 112 to 150. All of the included studies were published after 2015 and were single-institution studies.…”

“…On the other hand, the information from blood samples demonstrates only the indirect consequences of cancer progression. [34][35][36][37][38][39][40][41][42][43][44][45][46] Among these studies, only 1 study was prospective. Moreover, blood markers are not affected by any heterogeneity within the tumor.…”